Drug intelligence / Profile preview

bevacizumab + exemestane

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and exemestane, an aromatase inhibitor. This combination is primarily used for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. The treatment leverages dual mechanisms: bevacizumab inhibits the formation of new blood vessels that supply tumors by targeting VEGF, while exemestane reduces estrogen production, which is crucial for treating hormone receptor-positive breast cancers.

Targets

CYP19A1 (Aromatase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + exemestane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + exemestane.

Explore the full profile